Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
BMC Infectious Diseases|July 4, 2020
Fatal outcome in a patient under immunosuppressant therapy infected with human T-lymphotropic virus type 1 (HTLV-1), cytomegalovirus (CMV) and Strongyloides stercoralis: a case reportChisato Ashida, Koji Kinoshita, Yuji Nozaki, et al.
BMC Rheumatology|December 24, 2024
Utility of the GerdQ questionnaire in detecting gastroesophageal symptoms with RA patientsYuji Nozaki, Kazuya Kishimoto, Daisuke Tomita, et al.
Current Issues in Molecular Biology|March 26, 2025
Urinary Kim-1 Correlates with Interstitial Nephritis Activity in Patients with Microscopic PolyangiitisChisato Ashida, Yuji Nozaki, Jinhai Li, et al.
Frontiers in Medicine|November 15, 2023
Blockade of IL-18Rα-mediated signaling pathway exacerbates neutrophil infiltration in imiquimod-induced psoriasis murine modelHiroki Akazawa, Yuji Nozaki, Hirotaka Yamazawa, et al.
Lupus|October 28, 2022
U-KIM-1 as a predictor of treatment response in lupus nephritisYuji Nozaki, Toshihiko Shiga, Chisato Ashida, et al.
Biologics : Targets & Therapy|December 21, 2018
Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study resultsYuji Nozaki, Yasuaki Nagare, Chisato Ashida, et al.
Arthritis Research & Therapy|November 4, 2025
Stepwise dose reduction and discontinuation of bDMARD in rheumatoid arthritis: a prospective cohort study of flare-free population, flares, and predictive markersYuji Nozaki, Kazuya Kishimoto, Daisuke Tomita, et al.
Frontiers in Medicine|May 10, 2021
Real-World Methotrexate Dose on Clinical Effectiveness and Structural Damage of Certolizumab Pegol With Rheumatoid ArthritisYuji Nozaki, Toshihiko Hidaka, Jinhai Ri, et al.
Arthritis Research & Therapy|March 7, 2025
Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort studyAkira Onishi, Masao Tanaka, Takayuki Fujii, et al.
Rheumatology (Oxford, England)|March 20, 2025
Sustained efficacy of second-line JAK inhibitors in patients with rheumatoid arthritis: insights from the ANSWER CohortKohei Tsujimoto, Kosuke Ebina, Satomi Okamura, et al.
Pageof 2